, P ‫؍‬ ‫؍‬ .61) than did those with the DI (n ‫؍‬ ‫؍‬ 69) and II (n ‫؍‬ ‫؍‬ 65) genotypes. The deletion polymorphism of the ACE gene (P ‫؍‬ ‫؍‬ .04) was a significant predictor for carotid IMT on multiple regression analysis, controlling all the potential confounding factors including age (P ‫؍‬ ‫؍‬ .001), systolic blood pressure (P ‫؍‬ ‫؍‬ .09), smoking (P ‫؍‬ ‫؍‬ .08), and plasma tissue plasminogen activator antigen (P ‫؍‬ ‫؍‬ .03), but the LVM correlated only with age (P ‫؍‬ ‫؍‬ .02), sex (P < < .001), and body mass index (P < < .001). These results indicated that the DD genotype of the ACE gene could be considered a risk factor for the development of early atherosclerosis in carotid arteries but not for left ventricular hypertrophy in the hypertensive population. Am J Hypertens 2000;13:111-119
A common insertion/deletion (I/D) polymorphism characterized by the presence (I) or absence (D) of a 287-base pair alu repeat sequence in intron 16 of the angiotensin converting enzyme (ACE) gene has been reported to modulate the circulating and cellular ACE activity [1] [2] [3] and was shown to associate with myocardial infarction, 4, 5 and dilated 6, 7 and hypertrophic 8 cardiomyopathy, but not with hypertension. 1,9 -16 Several recent studies have further investigated the possible influence of the I/D polymorphism of the ACE gene on carotid atherosclerosis and cardiac hypertrophy. The D allele of the ACE gene was found to be a risk factor for increased carotid intima-medial thickness (IMT) in the general white population 17, 18 and in Japanese patients with non-insulin-dependent diabetes mellitus, 19 but not in a white low-risk population 20 and in white patients with ischemic stroke. 21 The DD genotype of the ACE gene was suggested to be a risk factor for left ventricular hypertrophy (LVH) in Japanese 22, 23 and white 24 -26 populations and patients with hypertension, but negative results were also reported in studies in whites by Lindpaintner et al, 27 Kupari et al, 28 and Wong et al. 29 A conclusive agreement about the role of ACE genotype in the genetics of cardiovascular diseases has not yet been reached. 30 -35 Furthermore, the association between ACE gene polymorphism and disease etiology may be varied among different ethnic populations and geographic areas. In the previous studies, 36, 37 we have shown that the ACE I/D genotype was not related to insulin resistance and impaired fibrinolysis in a Chinese population with hypertension living in the Taiwan area. In this study, we further test the hypothesis that the I/D polymorphism of the ACE gene may influence the phenotypic expression of carotid IMT and LVH detected by carotid ultrasound and echocardiography in a sample of Chinese outpatients with hypertension.
PATIENTS AND METHODS
This study was performed in 175 Chinese patients with mild-to-moderate hypertension who were recruited from cardiology clinic and fit the diagnostic criteria with diastolic blood pressure (BP) of 95 to 110 mm Hg on at least three separate occasions. The treated patients meet the mild-to-moderate hypertension criteria by the critical review of medical record and detail history taking of the BP level before treatment. They included 91 male and 84 female Chinese patients with age of 56.8 Ϯ 10.3 years, body mass index (BMI) of 25.9 Ϯ 3.3 kg/m 2 , and hypertension history of 7.3 Ϯ 7.9 years. About 71% were treated with antihypertensive drugs, including diuretics (n ϭ 25), ␤-adrenergic blockers (n ϭ 63), calcium channel antagonists (n ϭ 61), ACE inhibitors (n ϭ 40), and ␣-adrenergic blockers (n ϭ 23), for 6.4 Ϯ 7.8 years, and 31% of them were smokers. They volunteered to participate in this study following a protocol approved by the National Defense Medical Center Human Subjects Committee. Physical examination, review of medical history, and routine biochemistry were performed on each patient before entrance into this study. None of the study subjects had a history or clinical evidence of stroke, acute myocardial infarction, heart failure, or renal insufficiency. There was no apparent cause of secondary hypertension on clinical ground in all patients. Those patients with known diabetes or fasting plasma glucose concentration over 140 mg/dL were not included in this study.
Fasting blood samples were collected in the morning, spun within 1 hour, and the plasma separated and frozen at Ϫ70°C until the time of assay. Plasma values of glucose, total cholesterol, triglyceride, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (tPA) antigen were determined with commercially available kits as described previously. 38 Two-dimensionally guided M-mode and pulsed Doppler echocardiography were performed with a Hewlett Packard Sonos 5000 (Hewlett Packard, Andover, Massachusetts) using a 2.5-or 3.5-MHz transducer. M-mode measurement of interventricular septal thickness (IVST), left ventricular internal dimensions (LVDd), and posterior wall thickness (PWT) at end-diastole and left ventricular internal dimensions (LVDs) at end systole was performed at the left ventricular minor axis at the level of the chordae tendineae just beyond the mitral leaflet tips according to the Penn convention, 39 as recommended by the American Society of Echocardiography. 40 LVM was calculated using the formula of Devereux and
3 ) Ϫ 13.6 g and corrected for height (LVM/ht) and for body surface area (LVM index). Relative wall thickness (RWT) was obtained with the formula: [(PWT ϩ IVST)/LVDd], and fractional shortening (FS, %) derived from [(LVDd Ϫ LVDs)/LVDd] ϫ 100. Left ventricular end diastolic volume (LVEDV) was calculated from 7.0/(2.4 ϩ LVDd) ϫ LVDd 3 and corrected for body surface area (LVEDV index). Standard pulsed Doppler evaluation of LV inflow tract was performed from the apical 4-chamber view, with sample volume placed at the level of mitral valve leaflet tips and a strip-chart speed of 50 or 100 mm/s. The early filling peak transmitral flow velocity (peak E) and the late diastolic filling phase peak transmitral flow velocity (peak A) were measured, and the flow velocity E/A ratio was derived. All measurements were recorded on videotape by experienced technicians, verified by experts in echocardiography, and an average value of 3 to 6 beats was obtained for calculations.
Duplex ultrasound of carotid arteries was per-formed by a well-trained radiologist using an Acuson imager (Acuson Corporation, Mountain View, CA) with a 7-MHz transducer in B mode and an axial resolution of 0.15 mm. The carotid arteries were scanned on both sides from anterior oblique and lateral planes transversely and longitudinally. Measurement of the distance between the media-adventitia interface and the lumen-intima interface, so called IMT, was carried out on the far wall of the carotid bifurcation (BIF) and the common carotid artery (CCA) at 2 cm proximal to bifurcation. 42 Genomic DNA was extracted from 100-L buffy coat using an IsoQuick Nucleic Acid Extraction Kit (MicroProbe, Bothell, WA). The presence of the insertion and deletion allele in intron 16 of the ACE gene was detected using the method of Tiret et al. 2 The sequence of sense oligonucleotide primer was 5Ј-CTG GAG ACC ACT CCC ATC CTT TCT-3Ј and the antisense primer 5Ј-GAT GTG GCC ATC ACA TTC GTC AGA T-3Ј. Polymerase chain reaction (PCR) was performed with 80-ng genomic DNA in a final volume of 50 L containing 3 mmol/L MgCl 2 , 50 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.4, 0.1 mg/mL gelatin, 10 pmol of each primer, 200 mol/L of each dNTP, and 1 U Taq DNA polymerase (Promega, Madison, WI). Amplification was performed by using a DNA thermal cycler 480 (Perkin-Elmer Corporation, Norwalk, CT) with 1-min denaturation at 94°C, 1-min annealing at 55°C, and 2-min extension at 72°C for 30 cycles. In the last cycle the extension step was carried out for 10 min. PCR products were electrophoresed in 2% agarose gel and visualized directly with ethidium bromide staining. The insertion allele manifested as a 490-bp band, and the deletion allele was visualized as a 190-bp band.
All group data are reported as means Ϯ standard deviation (SD). The statistic significance of differences on mean levels of variables among three genotypes was examined by analysis of variance (ANOVA). Multiple regression was used to evaluate the association of ultrasound measures (LVM and carotid IMT) with ACE genotypes (DD v II and DD v DI), controlling all the potential confounding factors. The statistic significance of differences was assumed to be present at P Ͻ .05.
RESULTS
The percentages of the DD, DI, and II genotypes and the frequencies of the D and I alleles of the ACE gene in our hypertensive population were 23%, 39%, 37%, and 0.43, 0.57, respectively. Table 1 summarize the I/D genotype distribution and allele frequency in different ethnic populations with hypertension for comparison with our data. It can be noted that the percentage of the DD genotype was 20% to 52% among white patients with hypertension, 11, 12, 26, 32 18% to 21% among Japanese patients with hypertension, [13] [14] [15] and 40% to 43% among black patients with hypertension. 20, 43 The frequency of D allele was 0.34 to 0.56 among white patients with hypertension, 0.34 to 0.43 among Japanese patients with hypertension, and 0.60 to 0.64 among black patients with hypertension. The distribution of the I/D variant in our patients was significantly different from those of blacks and most whites with hypertension. However, there were no significant differences on DD genotype percentage between our data and those of Japanese populations with hypertension. [11] [12] [13] The DD genotype and D allele frequency in the Chinese hypertensive population at Beijing 35 were insignificantly lower than ours. The clinical characteristics of hypertension patients with ACE genotypes were shown in Table 2 . It can be noted that the history of hypertension and duration of antihypertensive treatment seemed shorter and the percentage of using ACE inhibitor greater in the DD genotype than in the DI and II genotypes but the differences were not statistically significant. In addition, three genotypic groups did not show significant difference on the mean values of age, gender, BMI, percentage and duration of antihypertensive therapy, systolic and diastolic BP, smoker status (P ϭ .07), fasting plasma glucose, total cholesterol, triglyceride, PAI-1 antigen, and tPA antigen. The proportion of patients on more than two antihypertensive medications to control hypertension was 43.9% for the DD allele, 29.0% for the II allele, and 43.1% for the DI allele, but the difference was not significant (F ϭ 1.86, P ϭ .16). Table 3 summarized the B-mode ultrasound measures of carotid IMT in three genotypic groups with hypertension. It can be seen that the left-sided, rightsided, and overall BIF and CCA showed greater average IMT values in the group with the DD genotype than in those with the DI and II genotypes but the difference reached statistical significance only on the right CCA (P ϭ .01). However, patients with the DD genotype had significantly greater mean values of maximal (P ϭ .01), mean (P ϭ .04), and minimal (P ϭ .02) carotid IMT measures than those with the DD and DI genotypes. About 37% of our patients with hypertension were found to have carotid plaque as defined by maximal carotid IMT measure Ͼ1.4 mm. The proportion of patients with carotid plaque criteria was significantly higher in the DD genotype than those in the DI and II genotypes (53.7% v 31.9% and 30.8%, F ϭ 3.45, P ϭ .03).
The M-mode and Doppler echocardiographic measures of the left ventricle in three genotypic groups with hypertension were displayed in Table 4 . There were no significant differences on the average values of IVST, PWT, LVDd, LVDs, RWT, FS, LVEDV, LVEDV index, peak E, peak A and E/A ratio among three genotypic groups. Data are expressed as means Ϯ SD.
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the proportion of patients having LVH criteria among the three groups with the DD, II, and DI allele (39%, 41.5%, and 46.4%, F ϭ 0.32, P ϭ .73). Table 5 showed multiple regression analysis of the factors relating to LVM and carotid IMT in patients with hypertension. Age (P ϭ .02), sex (P Ͻ .001), and BMI (P Ͻ .001) were significant determinants of LVM but the LVM did not have significant correlation with ACE genotypes in our population. On the other hand, ACE genotype (P ϭ .04) was a significant predictor for maximal carotid IMT measures in patients with hypertension after adjustment for age (P ϭ .001), sex, BMI, history of hypertension, duration and agents of antihypertensive treatment, systolic BP (P ϭ .09), diastolic BP, smoking habit (P ϭ .08), fasting plasma glucose, total cholesterol, triglyceride, PAI-1, and tPA antigens (P ϭ .03). The results of multiple regression analysis for LVM and carotid IMT were not significantly changed when the variables of PAI-1 and tPA were left out.
DISCUSSION
A positive correlation between the I/D polymorphism of the ACE gene and carotid IMT had been demon- 17, 18 and in Japanese patients with diabetes, 19 but, to the best of our knowledge, not yet in patients with hypertension. In this study, we first reported an association between the ACE I/D genotype and carotid IMT in Chinese patients with mild-to-moderate hypertension by direct B-mode ultrasound image. This association was not strong but statistically significant after adjustment for the confounding factors including age, smoking, systolic BP, and plasma tPA antigen. It indicated that the DD genotype might be an independent risk factor for early atherosclerosis and could interact with high BP to accelerate carotid thickening and plaque formation in the hypertensive population. In the absence of conventional major risk factors such as hypertension, diabetes, hyperlipidemia, and smoking, the DD genotype may have little contribution to later atherosclerosis. Evidences supporting this point of view came from a negative report on the association between the DD genotype and carotid IMT in a population without conventional major risk factors. 20 The lack of association between the DD genotype and carotid atheromatic stenosis in patients with a stroke 21 suggested the ACE gene effect may be outweighed by conventional major risk factors in the late atherosclerotic process.
The mechanism of ACE gene effect on carotid wall thickening is not clear at present. Because ACE I/D polymorphism was not associated with plasma angiotensin II (AII) levels, 10 the involvement of local RAS in ACE gene effect was logically proposed. A vascular hypertrophy can be found in the ACE-transfected blood vessel using an in vivo gene transfer technique. 44 Hence, a plausible explanation is that ACE genotypes contribute to carotid thickening through the genetically determination of vascular ACE activity. The DD genotype associated with higher endothelial ACE activity may predispose to carotid wall thickening through the action of increased AII production and bradykinin degradation resulting into neointimal proliferation, extracellular matrix deposition, and vascular hypertonicity. However, ACE I/D polymorphism may be only a marker associated with an unknown functional variant (ACE S/s) located near or within the ACE gene. 2 An alternative hypothesis is that the DD genotype of ACE was not directly involved but served as a genetic marker that linked to another closely located gene with direct effects on vascular growth regulation.
There are many contradictory reports [22] [23] [24] [25] [26] [27] [28] [29] on the role of ACE gene polymorphism in the development of LVH and this topic is controversial at present. In whites, the DD genotype has been shown to be a genetic risk factor of LVH in general population 24 and in patients with hypertension, 25, 26 but not in large population from the Framingham Heart Study. 27 In Japanese, a significant association of the I/D polymorphism with LVH was detected in male patients with various cardiovascular diseases, 22 in normotensive subjects, 23 and in hypertensive women. 24 However, in the Chinese patients with hypertension, we found lack of association between ACE genotype and LVM. This negative result was in accordance with those reports by Wong et al 29 in white patients and by Ohishi et al 23 in Japanese patients with hypertension. It may indicate that the DD genotype of the ACE gene was not an additional risk factor for LVH in the patients with hypertension and could play little role in the genesis of cardiac hypertrophy in face of high BP. Age, sex, and BMI were the only three independent predictors of LVM in our hypertensive population. In addition to these major determinants of LVH, the history of hypertension and antihypertensive treatment may also change the expression of ACE gene effect on LVM. More than two thirds of our patients were chronically treated and a higher, though statistically insignificant, percentage of antihypertensive treatment with the ACE inhibitor was noted in the group with the DD genotype. The ACE inhibitor has been suggested to be superior to other antihypertensive agents in inducing regression of LVH, even though they have similar effect on BP. 45 Furthermore, the proportion of our patients with the DD allele on more than two antihypertensive medications to control hypertension was higher than that of those patients with the II allele. It may also account for lack of association between LVH and the DD genotype. Therefore, we could not exclude the possibility that the ACE genotype may indeed influence the development and extent of LVH in patients with hypertension and the absence of association was either due to the confounding effect of antihypertensive treatment or relatively smaller sample size of untreated patients in our study. Although the place of the ACE gene effect in LVH is still uncertain, the importance of tissue ACE remains in cardiovascular diseases. Experimental studies have shown that AII is myotrophic and mitogenic for heart 46 and bradykinin have an antiproliferative effect. 47 In conclusion, the present study showed that, in a Chinese population with hypertension, patients with the DD genotype of the ACE gene had significant greater carotid IMT but not LVM index than did those with the DI and II genotypes. It suggested that the I/D polymorphism of the ACE gene could modify the phenotypic expression of carotid wall thickening but not cardiac hypertrophy in patients with hypertension. The DD genotype of the ACE gene may be considered a genetic risk factor for early atherosclerosis of carotid arteries but the I/D polymorphism might have trivial influence on LVM in patients with hypertension. However, the conclusions are limited to outpatients with hypertension recruited at a specialized department. It is not clear whether the restriction to this patient group introduced a selection bias and the findings may or may not reflect the situation in the overall population. Further large population-based case control study is needed to address some of the unresolved questions evolving from the present data.
